Saturday 17 October 2026
Export SLS’s income statement to Excel — free account
SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $1.0 million. In the quarter to June 2026, EPS grew 28.6% and free cash flow fell 3.52%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
9.98
1.36
−11.99%
Follow SLS
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 2,760.00 | 390.00 | 40.00 | 3.54 | 1.46 | 5.20 | 1.77 | 0.81 | 0.50 | 0.85 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 74,700.00 | 3,615.00 | 554.50 | 89.50 | 19.38 | 15.08 | 7.40 | 4.13 | 1.72 | 3.99 | |||||
| People | |||||||||||||||
| People | Employees | 14 | 9 | 9 | 5 | 7 | 11 | 17 | 16 | 15 | 13 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.27 | 0.69 | 0.06 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | 2 | 8 | 1 | — | — | — | ||||
| Gross margin, % | 0.00 | — | — | — | 100.00 | 97.37 | 90.00 | — | — | — | |||||
| EBT | (18) | (24) | (29) | (19) | (17) | (21) | (41) | (37) | (31) | (27) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | (882.84) | (275.47) | (4,130.10) | 0.00 | 0.00 | 0.00 | |||||
| Net income | (18) | (24) | (28) | (19) | (17) | (21) | (41) | (37) | (31) | (27) | |||||
| Depreciation | 0 | 0 | 9 | 3 | 0 | — | — | — | — | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.24 | 0.49 | 0.05 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (933.53) | (522.00) | (157.50) | (10.92) | (2.11) | (1.34) | (2.13) | (1.34) | (0.50) | (0.25) | |||||
| Cash flow | (626.98) | (234.81) | (116.11) | (6.89) | (1.31) | (1.68) | (1.23) | (1.13) | (0.58) | (0.26) | |||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.46) | (0.20) | 0.00 | 0.00 | |||||
| Free cash flow | (626.98) | (234.81) | (116.11) | (6.89) | (1.31) | (1.68) | (1.69) | (1.33) | (0.58) | (0.26) | |||||
| Book value | (264.39) | 44.23 | 20.02 | 2.38 | 3.51 | 1.31 | 0.25 | (0.29) | 0.15 | 0.65 | |||||
| Shares, m | 0 | 0 | 0 | 3 | 8 | 15 | 19 | 28 | 61 | 109 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | ||||
| P/S | — | — | — | — | 6.12 | 7.24 | 4.71 | — | — | — | |||||
| P/B | — | — | — | — | 1.66 | 4.21 | 10.20 | — | — | — | |||||
| EV/Sales | — | — | — | — | 1.56 | 5.48 | 3.11 | — | — | — | |||||
| EV/FCF | — | — | — | — | (1.13) | (2.48) | (1.15) | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (12) | (11) | (30) | (18) | (10) | (26) | (24) | (31) | (35) | (28) | ||||
| Capex | — | — | — | — | — | — | (9) | (5) | 0 | — | |||||
| Free cash flow | (12) | (11) | (30) | (18) | (10) | (26) | (33) | (37) | (35) | (28) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 1 | (11) | 0 | 3 | 25 | 18 | 2 | (11) | 7 | 68 | ||||
| Total debt | 7 | 11 | — | 0 | 1 | 1 | 1 | — | — | — | |||||
| Net debt | 1 | (2) | (5) | (7) | (35) | (21) | (17) | (3) | (14) | (72) | |||||
| Shareholders’ equity | (5) | 2 | 5 | 6 | 28 | 20 | 5 | (8) | 9 | 71 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (39.93) | (122.31) | (163.56) | (166.75) | (53.74) | (57.24) | (174.94) | (274.94) | (240.78) | (54.95) | ||||
| ROIC | 0.00 | (4,675.12) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | (415.24) | 1,669.22 | (1,127.85) | (493.05) | (98.87) | (85.70) | (327.81) | 2,389.76 | (4,147.88) | (66.88) | |||||
Negative figures in brackets.
Fiscal years to Dec 2022 · latest quarter Mar 2022
Charts ten years each
SELLAS Life Sciences Group, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ADMA ADMA Biologics Inc | $2.4B | 14.8× | 9.5× | +1.98% (above 0%: growing) | +21.43% (above 0%: growing) | +19.72% (above 0%: growing) | 69.36% | 42.16% | Compare |
| SLS SELLAS Life Sciences Group, Inc. | $2.3B | — (loss-making) | — (loss-making) | −57.10% (below 0%: shrinking) | n/m | −3.52% (below 0%: shrinking) | 0.00% | 0.00% | |
| CLDX Celldex Therapeutics, Inc. | $2.3B | — (loss-making) | — (loss-making) | −96.83% (below 0%: shrinking) | n/m | −35.45% (below 0%: shrinking) | 100.00% | (366,468.18%) | Compare |
| AUPH Aurinia Pharmaceuticals Inc | $2.2B | 6.9× | 16.5× | +18.87% (above 0%: growing) | +81.25% (above 0%: growing) | +19.08% (above 0%: growing) | 92.12% | 48.19% | Compare |
| HRMY Harmony Biosciences Holdings, Inc. | $2.2B | 12.2× | 9.4× | +30.32% (above 0%: growing) | +88.41% (above 0%: growing) | +16.53% (above 0%: growing) | 75.81% | 34.18% | Compare |
| RXRX Recursion Pharmaceuticals, Inc. | $2.2B | — (loss-making) | — (loss-making) | −60.10% (below 0%: shrinking) | n/m | −32.03% (below 0%: shrinking) | (49.82%) | (1,759.69%) | Compare |
| VRDN Viridian Therapeutics, Inc. | $2.2B | — (loss-making) | — (loss-making) | +278.67% (above 0%: growing) | n/m | −41.39% (below 0%: shrinking) | 100.00% | (44,460.56%) | Compare |
| IRON Disc Medicine, Inc. | $2.2B | — (loss-making) | — | — | n/m | +7.83% (above 0%: growing) | 0.00% | 0.00% | Compare |
| FTRE Fortrea Holdings Inc. | $2.2B | — (loss-making) | — (loss-making) | −4.52% (below 0%: shrinking) | n/m | +53.15% (above 0%: growing) | 20.52% | 2.18% | Compare |
| Median of peers | $2.2B | 12.2× | 9.5× | +1.98% | +81.25% | +12.18% | 72.59% | 1.09% |
SELLAS Life Sciences Group, Inc. (SLS) key facts
- SELLAS Life Sciences Group, Inc. (SLS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- SELLAS Life Sciences Group, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $1.0 million.
- As of October 16, 2026, SLS traded at $9.98, a market capitalization of $2.3 billion.
- Return on equity was −66.9% and debt-to-equity 0.00.
- Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −16.75 (distress zone) for fiscal 2022.